Rapid Biolayer Interferometry Measurements of Urinary CXCL9 to Detect Cellular Infiltrates Noninvasively After Kidney Transplantation

Ilaria Gandolfini; Cynthia Harris; Michael Abecassis; Lisa Anderson; Oriol Bestard; Giorgia Comai; Paolo Cravedi; Elena Cremaschi; J. Andrew Duty; Sander Florman; John Friedewald; Gaetano La Manna; Umberto Maggiore; Thomas Moran; Giovanni Piotti; Carolina Purroy; Marta Jarque; Vinay Nair; Ron Shapiro; Jessica Reid-Adam; Peter S. Heeger

doi:10.1016/j.ekir.2017.06.010

Kidney International Reports (Nov 2017)

Rapid Biolayer Interferometry Measurements of Urinary CXCL9 to Detect Cellular Infiltrates Noninvasively After Kidney Transplantation

Ilaria Gandolfini,
Cynthia Harris,
Michael Abecassis,
Lisa Anderson,
Oriol Bestard,
Giorgia Comai,
Paolo Cravedi,
Elena Cremaschi,
J. Andrew Duty,
Sander Florman,
John Friedewald,
Gaetano La Manna,
Umberto Maggiore,
Thomas Moran,
Giovanni Piotti,
Carolina Purroy,
Marta Jarque,
Vinay Nair,
Ron Shapiro,
Jessica Reid-Adam,
Peter S. Heeger

Affiliations

Ilaria Gandolfini: Translational Transplant Research Center, Icahn School of Medicine at Mount Sinai, New York, New York, USA
Cynthia Harris: Translational Transplant Research Center, Icahn School of Medicine at Mount Sinai, New York, New York, USA
Michael Abecassis: Comprehensive Transplant Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
Lisa Anderson: Translational Transplant Research Center, Icahn School of Medicine at Mount Sinai, New York, New York, USA
Oriol Bestard: Kidney Transplant Unit, Bellvitge University Hospital, IDIBELL, UB, Barcelona, Spain
Giorgia Comai: Department of Experimental, Diagnostic, Specialty Medicine, Nephrology, Dialysis, and Renal Transplant Unit, S. Orsola University Hospital, Bologna, Italy
Paolo Cravedi: Translational Transplant Research Center, Icahn School of Medicine at Mount Sinai, New York, New York, USA
Elena Cremaschi: Kidney and Kidney-Pancreas Unit, Department of Nephrology, Parma University Hospital, Parma, Italy
J. Andrew Duty: Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
Sander Florman: Recanati Miller Transplant Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
John Friedewald: Comprehensive Transplant Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
Gaetano La Manna: Department of Experimental, Diagnostic, Specialty Medicine, Nephrology, Dialysis, and Renal Transplant Unit, S. Orsola University Hospital, Bologna, Italy
Umberto Maggiore: Kidney and Kidney-Pancreas Unit, Department of Nephrology, Parma University Hospital, Parma, Italy
Thomas Moran: Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
Giovanni Piotti: Kidney and Kidney-Pancreas Unit, Department of Nephrology, Parma University Hospital, Parma, Italy
Carolina Purroy: Translational Transplant Research Center, Icahn School of Medicine at Mount Sinai, New York, New York, USA
Marta Jarque: Kidney Transplant Unit, Bellvitge University Hospital, IDIBELL, UB, Barcelona, Spain
Vinay Nair: Recanati Miller Transplant Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
Ron Shapiro: Recanati Miller Transplant Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
Jessica Reid-Adam: Division of Pediatric Nephrology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
Peter S. Heeger: Translational Transplant Research Center, Icahn School of Medicine at Mount Sinai, New York, New York, USA

DOI: https://doi.org/10.1016/j.ekir.2017.06.010
Journal volume & issue: Vol. 2, no. 6
pp. 1186 – 1193

Abstract

Read online

Measuring the chemokine CXCL9 in urine by enzyme-linked immunosorbent assay (ELISA) can diagnose acute cellular rejection (ACR) noninvasively after kidney transplantation, but the required 12- to 24-hour turnaround time is not ideal for rapid, clinical decision-making. Methods: We developed a biolayer interferometry (BLI)−based assay to rapidly measure urinary CXCL9 in 200 pg/ml in subjects with ACR and ≤100 pg/ml in subjects with stable kidney function without cellular infiltrates. In samples obtained after treatment for ACR, BLI CXCL9 measurements detected biopsy-proven intragraft infiltrates despite treatment-induced reduction in serum creatinine. Discussion: Together, our proof-of-principle results demonstrate that BLI-based urinary CXCL9 detection has potential as a point-of-care noninvasive biomarker to diagnose and guide therapy for ACR in kidney transplantation recipients.

Published in Kidney International Reports

ISSN: 2468-0249 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the genitourinary system. Urology
Website: http://www.journals.elsevier.com/kidney-international-reports/

About the journal

Abstract

Keywords